INCY - INCYTE CORP
98.86
0.790 0.799%
Share volume: 1,622,482
Last Updated: 03-04-2026
Business Services/Services – Research, Development, Testing Labs:
0.00%
PREVIOUS CLOSE
CHG
CHG%
$98.07
0.79
0.01%
Fundamental analysis
33%
Profitability
0%
Dept financing
42%
Liquidity
75%
Performance
52%
Performance
5 Days
-1.18%
1 Month
-3.80%
3 Months
-3.57%
6 Months
14.10%
1 Year
41.61%
2 Year
67.84%
Key data
Stock price
$98.86
DAY RANGE
$96.91 - $99.41
52 WEEK RANGE
$53.56 - $112.29
52 WEEK CHANGE
$41.05
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Recent news